Market closed
SpringWorks/$SWTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About SpringWorks
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
Ticker
$SWTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
368
Website
SpringWorks Metrics
BasicAdvanced
$2.6B
-
-$3.48
0.80
-
Price and volume
Market cap
$2.6B
Beta
0.8
52-week high
$62.00
52-week low
$28.21
Average daily volume
2.3M
Financial strength
Current ratio
3.805
Quick ratio
3.543
Long term debt to equity
1.285
Total debt to equity
1.645
Management effectiveness
Return on assets (TTM)
-26.48%
Return on equity (TTM)
-46.62%
Valuation
Price to revenue (TTM)
13.322
Price to book
5.32
Price to tangible book (TTM)
5.5
Price to free cash flow (TTM)
-13.003
Growth
Revenue change (TTM)
3,417.33%
Earnings per share change (TTM)
-32.39%
3-year earnings per share growth (CAGR)
-0.98%
What the Analysts think about SpringWorks
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for SpringWorks stock.
SpringWorks Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SpringWorks Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SpringWorks News
AllArticlesVideos
SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz
Seeking Alpha·1 month ago
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
GlobeNewsWire·2 months ago
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for SpringWorks stock?
SpringWorks (SWTX) has a market cap of $2.6B as of April 12, 2025.
What is the P/E ratio for SpringWorks stock?
The price to earnings (P/E) ratio for SpringWorks (SWTX) stock is 0 as of April 12, 2025.
Does SpringWorks stock pay dividends?
No, SpringWorks (SWTX) stock does not pay dividends to its shareholders as of April 12, 2025.
When is the next SpringWorks dividend payment date?
SpringWorks (SWTX) stock does not pay dividends to its shareholders.
What is the beta indicator for SpringWorks?
SpringWorks (SWTX) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.